|
|
|
|
LEADER |
00000nam a22000005i 4500 |
001 |
978-3-319-42223-7 |
003 |
DE-He213 |
005 |
20220117131530.0 |
007 |
cr nn 008mamaa |
008 |
160830s2016 sz | s |||| 0|eng d |
020 |
|
|
|a 9783319422237
|9 978-3-319-42223-7
|
024 |
7 |
|
|a 10.1007/978-3-319-42223-7
|2 doi
|
050 |
|
4 |
|a RC261-271
|
072 |
|
7 |
|a MJCL
|2 bicssc
|
072 |
|
7 |
|a MED062000
|2 bisacsh
|
072 |
|
7 |
|a MJCL
|2 thema
|
082 |
0 |
4 |
|a 571.978
|2 23
|
082 |
0 |
4 |
|a 616.994
|2 23
|
245 |
1 |
0 |
|a Defects in T Cell Trafficking and Resistance to Cancer Immunotherapy
|h [electronic resource] /
|c edited by Emmanuel Donnadieu.
|
250 |
|
|
|a 1st ed. 2016.
|
264 |
|
1 |
|a Cham :
|b Springer International Publishing :
|b Imprint: Springer,
|c 2016.
|
300 |
|
|
|a VIII, 199 p. 27 illus., 19 illus. in color.
|b online resource.
|
336 |
|
|
|a text
|b txt
|2 rdacontent
|
337 |
|
|
|a computer
|b c
|2 rdamedia
|
338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
347 |
|
|
|a text file
|b PDF
|2 rda
|
490 |
1 |
|
|a Resistance to Targeted Anti-Cancer Therapeutics,
|x 2196-551X ;
|v 9
|
505 |
0 |
|
|a Introduction -- Basic rules of T cell migration -- Regulation of anti-tumor T cell migration and function: contribution of real-time imaging -- Vascular normalization, T cell trafficking and anti-tumor immunity -- Disruption of anti-tumor T cell responses by cancer-associated fibroblasts -- Cancer-associated Tertiary Lymphoid Structures, from basic knowledge toward therapeutic target in clinic -- Homing Improvement: Boosting T Cell Trafficking for Cancer Immunotherapy -- Chemokines and T cell trafficking into tumors. Strategies to enhance recruitment of T cells into tumors -- Strategies to enhance migration and persistence of chimeric antigen receptor (CAR)-T cells into tumors.
|
520 |
|
|
|a This volume focuses on recent advances in understanding T cells as key players in antitumor immune responses, and as a result T cell-based immunotherapy is starting to transform the treatment of advanced cancers. However, despite recent successes, many patients with cancer fail to respond to these treatments. Defective migration of T cells into and within tumors is considered as an important resistance mechanism to cancer immunotherapy. The volume includes three sections. The first section covers general knowledge about T cell trafficking during a normal immune response but also during tumor development. The second section provides an in-depth description of the different obstacles that prevent T cells from migrating and contacting tumor cells. The third section explores therapeutic strategies to improve trafficking of T cells into tumors and, thus, to enhance the effectiveness of cancer immunotherapy.
|
650 |
|
0 |
|a Cancer.
|
650 |
|
0 |
|a Immunology.
|
650 |
|
0 |
|a Medicine-Research.
|
650 |
|
0 |
|a Biology-Research.
|
650 |
1 |
4 |
|a Cancer Biology.
|
650 |
2 |
4 |
|a Immunology.
|
650 |
2 |
4 |
|a Biomedical Research.
|
700 |
1 |
|
|a Donnadieu, Emmanuel.
|e editor.
|4 edt
|4 http://id.loc.gov/vocabulary/relators/edt
|
710 |
2 |
|
|a SpringerLink (Online service)
|
773 |
0 |
|
|t Springer Nature eBook
|
776 |
0 |
8 |
|i Printed edition:
|z 9783319422213
|
776 |
0 |
8 |
|i Printed edition:
|z 9783319422220
|
776 |
0 |
8 |
|i Printed edition:
|z 9783319825281
|
830 |
|
0 |
|a Resistance to Targeted Anti-Cancer Therapeutics,
|x 2196-551X ;
|v 9
|
856 |
4 |
0 |
|u https://doi.uam.elogim.com/10.1007/978-3-319-42223-7
|z Texto Completo
|
912 |
|
|
|a ZDB-2-SBL
|
912 |
|
|
|a ZDB-2-SXB
|
950 |
|
|
|a Biomedical and Life Sciences (SpringerNature-11642)
|
950 |
|
|
|a Biomedical and Life Sciences (R0) (SpringerNature-43708)
|